Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

You may be eligible if

• Patient Selection
• Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma
• Presence of known sensitizing mutations in EGFR TK domain
• Consented to HRPO# 201305031 ("Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected -Thoracic Malignancies, or Mesothelioma")
• Treatment with standard of care erlotinib
• At least 18 years of age